Qing Zhu

Qingzhu Biopharma is a clinical-stage biotechnology company based in Suzhou, China, dedicated to the development of next-generation multi-specific antibody therapies for cancer and immunological disorders. The company leverages its proprietary technology platforms to engineer complex biologics, such as bifunctional fusion proteins and bispecific antibodies, that can simultaneously modulate multiple therapeutic targets. Its lead candidate, QZ-001, is a PD-L1/TGF-beta trap fusion protein currently in Phase 1 clinical trials for advanced solid tumors. Another key program, QZ-002, is a bispecific antibody targeting Claudin 18.2 and 4-1BB, designed to provide localized immune activation within the tumor microenvironment. Qingzhu is supported by a syndicate of leading life science investors and aims to provide more effective treatment options for patients who do not respond to current standard-of-care immunotherapies.